Dr. Kang's paper Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clinical Cancer Research 15:1126-1132, 2009. (PMCID: PMC3182268) has been cited 500 times. It was the most cited paper in Clinical Cancer Research in 2009, and it has continued to be cited since 2009. Clinical Cancer Research ranks 5th of all journals in Oncology. Dr. Kang's paper is the 2nd most cited paper in Clinical Cancer Research of all papers published in that journal in the last 5 years.
St Baldrick's has once again provided a generous grant to the TTUHSC Cancer Center to support clinical research associates that assist with pediatric oncology clinical trials. We are most grateful to St Baldrick's for their support of pediatric oncology clinical trials.
Oct 1st: School of Medicine, Red Raider cross country join forces for ALSF. The School of Medicine Cancer Center at Texas Tech University Health Sciences Center (TTUHSC) received a three year grant from Alex's Lemonade Stand Foundation (ALSF) to support the Children's Oncology Group Cell Line and Xenograph Repository. During National Childhood Cancer Awareness Month, the School of Medicine Cancer Center also partnered with the Texas Tech University cross country team in its effort to journey one million miles for ALSF. Read the full story at the Daily Dose.
Oct 1st: Alex's Lemonade Stand Foundation (www.alexslemonade.org) which generously supports the COG Cell Line and Xenograft Repository housed at the TTUHSC SOM Cancer Center sponsored the Alex's Million Mile event for Childhood Cancer Month (Sept). Participants in the event log miles running, walking, cycling during Sept with a goal to reach a million miles for childhood cancer awareness. This year over 800,000 miles were logged. Teams can log miles that bring in contributions per mile for research groups and labs, and Team Cell Busters was formed to support the COG Cell Line and Xenograft Repository (www.COGcell.org), which is located in the TTUHSC SOM Cancer Center. COGcell grows childhood cancer cells in the lab and provides these research models to investigators in 15 countries. Cellbusters logged 15324.8 miles, aided greatly by the Texas Tech Cross Country team being part of this event.
Oct 1st: Dr. Mohamad Al-Rahawan has joined TTUHSC as Division Head, Pediatric Hematology-Oncology. Dr. Al-Rahawan comes to us from the St. Jude Midwest Affiliate and The University of Illinois College of Medicine at Peoria.
Sept 1st: Alex's Lemonade Stand Foundation (www.alexslemonade.org) has provided a generous 3 year grant to the TTUHSC School of Medicine Cancer Center to support the COG Cell Line and Xenograft Repository (www.COGcell.org), which is located in the TTUHSC SOM Cancer Center. COGcell grows childhood cancer cells in the lab and provides these research models to investigators in 15 countries.
The Cancer Prevention & Research Institute of Texas (CPRIT), has awarded Dr. Min Kang, head of the Cancer Center Pharmacology Program an individual investigator grant to conduct pharmacokinetic and pharmacogenomics studies in children with cancer. This grant expands ongoing studies Dr. Kang is carrying out together with the Children's Oncology Group and the New Approaches to Neuroblastoma Therapy (NANT) consortium.
C Patrick Reynolds, MD PhD, Director of the TTUHSC SOM Cancer Center had the pleasure of visiting with the children of Littlefield Primary School to celebrate the completion of their amazing fund raising efforts for the Children's Neuroblastoma Cancer Foundation (CNCF). Dr. Reynolds was asked to represent the CNCF at the event as he is a member of their Medical & Scientific Advisory Board. All funds raised by the Littlefield students went directly to the CNCF to help with their great work supporting families of children with neuroblastoma and research on neuroblastoma. View a video of the amazing Littlefield children and teachers here: http://www.kcbd.com/story/25033353/littlefield-students-raise-over-1300-for-cancer-research
Dr. Barry Maurer has activated a new clinical trial in the South Plains Oncology Consortium (SPOC) for patients with high-risk neuroblastoma. As a result of his recent publication describing the clinical activity in high-risk neuroblastoma of the novel LXS oral powder fenretinide formulation that Dr. Maurer developed, Dr. Maurer (who sponsors the Investigational New Drug Application with the Food & Drug Administration for this new drug) and the FDA determined that it was appropriate to have a clinical study providing compassionate access to this new drug for children with recurrent neuroblastoma. This clinical trial is not designed to collect research data but rather to provide access for an active drug to children in need. Physicians, patients, or families can contact the SPOC operations office to learn more about this clinical trial.
The South Plains Oncology Consortium (SPOC) has begun entering patients on its latest pediatric oncology phase I trial which tests a novel nanoliposomal irinotecan (MM-398) developed by Merrimack Pharmaceuticals in children with recurrent solid tumors. The trial was based on preclinical work done at the TTUHSC SOM Cancer Center by Drs Kang and Reynolds. The study chair for the SPOC study of MM-398 is Dr. Paul Harker-Murray of Midwest Children's Cancer Center.
St Baldrick's has awarded a Pediatric Oncology Infrastructure Grant to Dr. C Patrick Reynolds, Director of the TTUHSC SOM Cancer Center. This grant will support clinical research associates who are essential for managing data and sample flow for children entered onto pediatric oncology clinical trials.
Texas Tech University Health Sciences Center School of Medicine Cancer Center, 3601 4th Street STOP 9445, Lubbock, TX 79430-6450
T: 806.743.1558 Cancer Center Webmaster